Bing-He Xu Bing H. Xu Binghe Xu - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

All papers authored by Bing-He Xu Bing H. Xu Binghe Xu

This paper is made freely available by the publisher.

2024 Yun Wu, Hongnan Mo, Hangcheng Xu, Yan Wang, Jiayu Wang, Fei Ma

ORCID

, Binghe Xu

ORCID

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study

Download from doi.org

This paper is made freely available by the publisher.

Sarina A. Piha-Paul

ORCID

, Binghe Xu

ORCID

, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, David S. Hong, Jordi A. Rodon, Apostolia M. Tsimberidou, Kanwal Raghav, Jaffer A. Ajani

ORCID

, Anthony P. Conley, Frank Mott, Ying Fan, Jean Fan and 10 other authors

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

Download from doi.org

This paper is made freely available by the publisher.

2023 Junning Cao, Hongqian Guo, Dongmei Ji, Weina Shen, Shun Zhang, Chih-Yi Hsieh, Sui Xiong Cai, Ye Edward Tian, Cong Xu, Pin Zhang

ORCID

, Binghe Xu

ORCID

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Mingxia Jiang, Jiaxuan Liu, Qiao Li

ORCID

, Binghe Xu

ORCID

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status

Upload

This paper was not found in any repository, but could be made available legally by the author.

Yang Luo, Ying Cheng, Chunjiao Wu, Hui Ye, Naihan Chen

ORCID

, Fan Zhang, Hua Wei, Binghe Xu

ORCID

Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors

Upload

This paper is made freely available by the publisher.

Fengzhu Guo

ORCID

, Jialu Ma, Cong Li, Shuning Liu, Weizheng Wu, Chunxiao Li, Jiani Wang, Jinsong Wang, Zhijun Li, Jingtong Zhai, Fangzhou Sun, Yantong Zhou, Changyuan Guo

ORCID

ORCID

, Binghe Xu

ORCID

PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Fengzhu Guo

ORCID

, Cong Li, Shuning Liu, Zhijun Li, Jingtong Zhai, Zhiwu Wang, Binghe Xu

ORCID

High BRCA1 expression is an independent prognostic biomarker in LUAD and correlates with immune infiltration

Upload

This paper is made freely available by the publisher.

Yiqun Han, Jiayu Wang

ORCID

, Binghe Xu

ORCID

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer

Download from doi.org

This paper is made freely available by the publisher.

Jingtong Zhai

ORCID

, Yun Wu

ORCID

, Fei Ma

ORCID

, Virginia Kaklamani

ORCID

, Binghe Xu

ORCID

Advances in medical treatment of breast cancer in 2022

Download from onlinelibrary.wiley.com

This paper is made freely available by the publisher.

Binghe Xu

ORCID

, Fei Ma, Tao Wang, Shusen Wang

ORCID

, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng and 3 other authors

A Phase IIb , single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments

Download from onlinelibrary.wiley.com

This paper is made freely available by the publisher.

Zhijun Li

ORCID

ORCID

ORCID

, Binghe Xu

ORCID

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy

Download from doi.org

This paper is made freely available by the publisher.

2022 Jiani Wang, Yiqun Han

ORCID

, Jiayu Wang, Qing Li, Binghe Xu

ORCID

Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

Binghe Xu

ORCID

, Wei Li, Qingyuan Zhang, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, Yongmei Yin, Hong Zheng, Jifeng Feng, Huaqi Zhu, Asna Siddiqui, Harrison Macharia, Adam Knott

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study

Upload

This paper is made freely available by the publisher.

Binghe Xu

ORCID

, Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shouman Wang, Xiaojia Wang, Zhongsheng Tong, Yahua Zhong, Jiayu Wang, Min Yan and 10 other authors

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Download from link.springer.com

This paper is made freely available by the publisher.

Di Zhang, Jingtong Zhai, Lixi Li, Yun Wu, Fei Ma, Binghe Xu

ORCID

Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study

Download from doi.org

This paper is made freely available by the publisher.

Ruoxi Hong, Binghe Xu

ORCID

Breast cancer: an up‐to‐date review and future perspectives

Download from doi.org

This paper is made freely available by the publisher.

Hangcheng Xu, Yiqun Han

ORCID

, Yun Wu, Yan Wang, Jiayu Wang

ORCID

, Binghe Xu

ORCID

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis

Download from onlinelibrary.wiley.com

This paper is made freely available by the publisher.

Yiqun Han, Yun Wu, Hangcheng Xu, Jiayu Wang

ORCID

, Binghe Xu

ORCID

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study

Download from link.springer.com

This paper is made freely available by the publisher.

2021 Binghe Xu

ORCID

, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang and 11 other authors

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Download from www.nature.com

This paper was not found in any repository, but could be made available legally by the author.

Yuanyuan Zhang, Hongyan Chen, Hongnan Mo

ORCID

, Xueda Hu, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu and 5 other authors

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Upload

Missing publications? Search for publications with a matching author name.